Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

Tiago Torres; Anne Sohrt Petersen; Ulla Ivens; Albert Bosch Vilaro; John Stinson; José Manuel Carrascosa

doi:10.1007/s13555-024-01143-x

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

Dermatol Ther (Heidelb). 2024 Apr;14(4):983-992. doi: 10.1007/s13555-024-01143-x. Epub 2024 Apr 13.

Authors

Tiago Torres¹, Anne Sohrt Petersen², Ulla Ivens³, Albert Bosch Vilaro³, John Stinson³, José Manuel Carrascosa⁴

Affiliations

¹ Centro Hospitalar Universitário de Santo António, University of Porto, Porto, Portugal.
² LEO Pharma A/S, Industriparken 55, 2750, Ballerup, Denmark. oypdk@leo-pharma.com.
³ LEO Pharma A/S, Industriparken 55, 2750, Ballerup, Denmark.
⁴ Hospital Universitari Germans Trias I Pujol, UAB, IGTP, Badalona, Spain.

Abstract

Introduction: Tralokinumab and dupilumab are biological agents licensed for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who are candidates for systemic treatment. However, no head-to-head studies of their efficacy have been conducted. This study indirectly compared the efficacy of tralokinumab and dupilumab, both in combination with topical corticosteroids (TCS), at week 32.

Methods: An unanchored matching-adjusted indirect comparison was conducted using individual patient data (IPD) from the ECZTRA 3 tralokinumab trial and aggregate data from the LIBERTY AD CHRONOS dupilumab trial. IPD were selected by applying inclusion criteria from LIBERTY AD CHRONOS and weighting to match summary baseline characteristics-age, sex, race, body mass index, disease duration, Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Dermatology Life Quality Index (DLQI) and SCORing Atopic Dermatitis index-of patients treated with dupilumab. Week 32 outcomes of interest were 50%, 75% or 90% improvements in EASI (EASI-50, EASI-75 and EASI-90), IGA scores of 0 or 1 (IGA 0/1), ≥ 4-point improvement in worst daily pruritus numerical rating scale (NRS) score, and mean improvements in DLQI and the Patient Oriented Eczema Measure (POEM).

Results: After matching, tralokinumab and dupilumab, both in combination with TCS, showed similar efficacy across clinical response endpoints at week 32 (IGA 0/1, tralokinumab 49.9% vs dupilumab 39.3%; EASI-50, 78.9% vs 77.5%; EASI-75, 71.5% vs 71.9%; EASI-90, 53.3% vs 56.2%). The mean change from baseline in DLQI was statistically significantly larger in the matched tralokinumab plus TCS population than in the dupilumab plus TCS arm (- 12.1 vs - 10.4, p = 0.005). Changes in POEM and worst daily pruritus NRS were similar in the two groups.

Conclusion: The results of this analysis demonstrate that, in combination with TCS, tralokinumab and dupilumab have similar efficacy in the treatment of moderate-to-severe AD at 32 weeks of therapy.

Keywords: Atopic dermatitis; Dupilumab; Matching-adjusted indirect comparison; Topical corticosteroids; Tralokinumab.